Effects of Ca2+ channel blockers on apomorphine, bromocriptine and morphine-induced locomotor activity in mice

European Journal of Pharmacology

Volumn 364, Issue 2-3, 1999, Pages 175-182

  Dogrul, Ahmet ^a   Yeşilyurt, Özgür ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Ca2+ channel blocker; Dopamine; Locomotor activity

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMLODIPINE; APOMORPHINE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DOPAMINE RECEPTOR; HALOPERIDOL; MORPHINE; NICARDIPINE; NIFEDIPINE; VERAPAMIL; DOPAMINE RECEPTOR BLOCKING AGENT; FUSED HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; MOTOR ACTIVITY; MOUSE; TIME;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; AMLODIPINE; ANIMALS; APOMORPHINE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MICE; MORPHINE; MOTOR ACTIVITY; NICARDIPINE; TIME FACTORS; VERAPAMIL;

EID: 0032587005     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00640-2     Document Type: Article

References (54)

1. Antkiewicz-Michaluk L., Michaluk J., Romanska I., Vetulani J. Cortical dihydropyridine binding sites and behavioral syndrome in morphine abstinent rat. Eur. J. Pharmacol. 180:1990;129-135.
2. Antkiewicz-Michaluk L., Michaluk J., Romanska I., Vetulani J. Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology. 111:1993;457-464.
3. Antkiewicz-Michaluk L., Michaluk J., Romanska I., Vetulani J. Differential involvement of voltage-dependent calcium channels in apomorphine-induced hypermotility and stereotypy. Psychopharmacology. 113:1994;555-560.
4. 2+ channel blockade with nifedipine. Eur. J. Pharmacol. 254:1994;9-16.
5. Ayhan I.H., Randrup A. Behavioural and pharmacological studies on morphine-induced excitation of rats. Possible relation to brain catecholamines. Psychopharmacology (Berlin). 29:1973;317-328.
6. Bagchi S.P. Antidopaminergic action of verapamil and several other drugs: inactivation of vesicular dopamine. Life Sci. 46:1990;857-863.
7. Bedingfield J.B., Calder L.D., Karler R. Comparative behavioral sensitization to stereotypy by direct and indirect dopamine agonists in CF-1 mice. Psychopharmacology. 124:1996;219-225.
8. Bourson A., Gower A.J., Mir A.K., Moser P.C. The effects of dihydropyridine compounds in behavioral test of dopaminergic activity. Br. J. Pharmacol. 98:1989;1312-1318.
9. Cabib S., Puglisi-Allegra S. A classical genetic analysis of two apomorphine-induced behaviors in the mouse. Pharmacol. Biochem. Behav. 30:1988;143-148.
10. Carroll B.J., Sharp P. Monoamine mediation of the morphine induced activation of mice. Br. J. Pharmacol. 46:1972;124-139.
11. 2 -dopamine receptor modification in rat striatum after calcium channel blocker treatment. Meth. Find. Exp. Clin. Pharmacol. 12:1990;609-611.
12. 3H -spiperone binding to the porcine anterior pituitary Life Sci. 30:1982;1385-1389.
13. 3H ] spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations Eur. J. Pharmacol. 106:1985;133-139.
14. Di Chiara G., Imperato A. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol and barbiturates: studies with transcerebral brain dialysis in freely moving rats. Ann. New York Acad. Sci. 473:1986;367-381.
15. Di Chiara G., Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244:1988;1067-1080.
16. Di Chiara G., Porceddu M.L., Vargui L., Stefanini E., Gessa G.L. Evidence for selective and long-lasting stimulation of 'regulatory' dopamine-receptors by bromocriptine (CB-154). Naunyn-Schmiedeberg's Arch. Pharmacol. 300:1977;239-245.
17. Dogrul A., Yeşilyurt Ö., Deniz G., Işimer A. Analgesic effects of amlodipine and its interaction with morphine and ketorolac. Gen. Pharmacol. 29:1997;835-845.
18. Fuxe K., Fredholm B.B., Agnati L.F., Ogren S.-O., Everitt B.J., Johnson G., Gustafsson J.-A. Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology. 16:1978;99-134. (Suppl 1).
19. Gaggi R., Cont R., Gianni A.M. Comparison among the effects of nifedipine, nimodipine and nisoldipine on the brain biogenic amines of normal or haloperidol treated rats. Gen. Pharmacol. 24:1993;1091-1096.
20. Grebb J.A., Shelton R.J., Freed W.C. Diltiazem or verapamil prevents haloperidol-induced apomorphine supersensitivity in mice. J. Neural. Transm. 68:1987;241-255.
21. Jackson D.M., Hashizume M. Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors. J. Neural. Transm. 69:1987;131-145.
22. Jackson D.M., Jenkins O.F. Hypothesis: Bromocriptine lacks intrinsic dopamine receptor stimulating properties. J. Neural. Transm. 62:1985;219-230.
23. Jackson D.M., Jenkins O.F., Ross S.B. The motor effects of bromocriptine. Psychopharmacology. 95:1988;433-446.
24. Jackson D.M., Martin L.P., Larsson L.G., Cox R.F., Waszczak B.L., Ross S.B. Behavioral, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;290-299.
25. Jackson D.M., Mohell N., Georgiev J., Bengtsson A., Larsson L.G., Magnusson O., Ross S.B. Time course of bromocriptine induced excitation in the rat: behavioral and biochemical studies. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:1995;146-155.
26. Jacquet Y.F., Saederup E., Squires R.F. Non-stereospecific excitatory actions of morphine may be due to GABA-A receptor blockade. Eur. J. Pharmacol. 138:1987;285-288.
27. Jenkins O.F., Jackson D.M. Bromocriptine potentiates the behavioral effects of directly and indirectly acting dopamine receptor agonists in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 331:1985;7-11.
28. Johnson A.M., Loew D.M., Vigouret J.M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (±)amphetamine and L-DOPA. Br. J. Pharmacol. 56:1976;59-68.
29. Kato T., Otsu Y., Furune Y., Yamamoto T. Different effects of L-, N- and T-type calcium channel blockers on striatal dopamine release measured by microdialysis in freely moving rats. Neurochem. Int. 21:1992;99-107.
30. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain. Res. 94:1975;507-522.
31. Longoni R., Spina L., Di Chiara G. Dopaminergic D-1 receptors: essential role in morphine-induced hypermotility. Psychopharmacology. 93:1987;401-402.
32. Magnus-Ellenbroek B., Havemann-Reinecke U. Morphine-induced hyperactivity in rats - a rebound effect? Naun-Schmiedeberg's Arch. Pharmacol. 347:1993;635-642.
33. Maiolini Junior M., Mattia N.F., Conceicao I.M., Chang Y.H., Smaili S., Frussa-Filho R. Effects of single and long-term administration of nifedipine on dopamine-related behaviors. Braz. J. Med. Biol. Res. 27:1994;725-730.
34. Mamczarz J., Karolewicz B., Antkiewicz-Michaluk L., Vetulani J. Co-administration of nifedipine with neuroleptics prevents development of activity changes during withdrawal. Pol. J. Pharmacol. 46:1994;75-77.
35. Martin M.I., Lizasoain I., Leza J.C. Calcium channel blockers: effect on morphine-induced hypermotility. Psychopharmacology. 101:1990;267-270.
36. Mena M.A., Garcia de Yebenes M.J., Tabernero C., Casarejos M.J., Pardo B., Garcia de Yebetes J. Effects of calcium antagonists on dopamine system. Clin. Neuropharmacol. 18:1995;410-426.
37. Miller R.J. Multiple calcium channels and neuronal function. Science. 235:1987;46-52.
38. Nordström O., Braesch-Andersen S., Bartfai T. Dopamine release is enhanced while acetylcholine release is inhibited by nimodipine. Acta Physiol. Scand. 126:1986;115-119.
39. Oka T., Hosoya E. Effects of humoral modulators and naloxone on morphine-induced changes in the spontaneous locomotor activity of rat. Psychopharmacology (Berlin). 47:1976;243-248.
40. Oliverio A. Genotype-dependent electroencephalographic, behavioral and analgesic correlates of morphine: an analysis in normal mice and mice with septal lesions. Brain Res. 83:1975;135-141.
41. Oliverio A., Castellano C. Genotype-dependent sensitivity and tolerance to morphine and heroin: dissociation between opiate-induced running and analgesia in the mouse. Psychopharmacology. 39:1974;13-22.
42. Pavone F., Battaglia M., Sansone M. Nifedipine-morphine interaction: a further investigation on nociception and locomotor activity in mice. J. Pharm. Pharmacol. 44:1992;773-776.
43. 2+ antagonist nimodipine on dopamine metabolism in mouse brain. J. Neural Transm. 66:1986;171-178.
44. Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology. 109:1992;12-29.
45. Rethy C.R., Smith C.B., Villarreal J.E. Effects of narcotic analgesia upon the locomotor activity and brain catecholamine content of the mouse. J. Pharmacol. Exp. Ther. 176:1971;472-479.
46. Sansone M., D'Udine B., Renzi P., Vetulani J. Antihistaminics enhance morphine, amphetamine and scopolamine-induced hyperactivity in mice. Psychopharmacology. 93:1987;155-157.
47. Shannon H.E., Bemis K.G., Peters S.C. Potency and efficacy of dopamine agonists in mouse strains differing in dopamine cell and receptor number. Pharmacol. Biochem. Behav. 40:1991;103-107.
48. Skrinskaya J.A., Nikulina E.M., Popova N.K. Role of genotype in brain dopamine metabolism and dopamine-dependent behavior of mice. Pharmacol. Biochem. Behav. 42:1992;261-267.
49. Starke K., Späth L., Wichmann T. Effects of verapamil, diltiazem and ryosidine on the release of dopamine and acetylcholine in rabbit caudate nucleus slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 325:1984;124-130.
50. Swanson T.H., Green C.L. Nifedipine: more than a calcium channel blocker. Gen. Pharmacol. 17:1986;255-260.
51. Tsuda K., Tsuda S., Masuyama Y. Effects of calcium-antagonists on dopamine release in the central nervous system. Jpn. Circ. J. 56:1992;248-254.
52. Vaccarino F.J., Amalric M., Swerdlow N.R., Koob G.F. Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in the rat. Pharmacol. Biochem. Behav. 24:1986;61-65.
53. Zarrindast M.R., Eliassi A. Differential effects of dopamine agonists on locomotion in intact and reserpine treated mice. Gen. Pharmacol. 22:1991;1027-1031.
54. Zarrindast M.R., Zarghi A. Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible D-1 and D-2 receptor involvement. Gen. Pharmacol. 23:1992;1221-1225.